The long-term clinical outcomes of patients with hepatitis B virus (HBV)-related cirrhosis receiving nucleos(t)ide analog (NA) therapy according to virological response patterns remain inadequately defined. This study aimed to investigate the association between virological response patterns and clinical outcomes in a large, long-term, real-world cohort.

A new ultrasonic needle for tumour diagnostics has been trialled in collaboration with Aalto University and Helsinki University Hospital (HUS). The needle allows for 2-3x more tissue to be sampled, less invasively, indicating strong potential for significantly higher accuracy in diagnostics.

Invariant natural killer T (iNKT) cells are promising for cancer immunotherapy because they can coordinate broader immune responses, but sourcing enough functional cells is challenging. In a recent study, researchers from Japan showed that combining stem cell-derived iNKT cells with an immune-activating lipid compound can strongly suppress tumors in mice by training the body’s own T cells to recognize and remember cancer. These findings point to a more effective and scalable form of immunotherapy.

Robot-assisted radical prostatectomy (RARP) has become the standard treatment for localized prostate cancer. However, postoperative urinary incontinence and erectile dysfunction remain common complications. A new review published in UroPrecision systematically examines nerve-sparing techniques during RARP, including anatomical foundations, surgical planes, innovative approaches, and patient selection tools, providing a practical guide for balancing cancer control and functional preservation.

A research team from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has uncovered the mechanism underlying how cancer patients respond to a widely used cancer drug, known as paclitaxel, offering insights that may help overcome cancer drug resistance. The study found that small differences in microtubules, the structures inside cells that help the cells divide and move, can determine the efficacy of paclitaxel. This finding was published in Nature Chemical Biology.

The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in a phase 1/2 first-in-human trial in patients with previously treated, RAS-mutant, metastatic pancreatic cancer, according to a clinical trial led at Dana-Farber Cancer Institute and across the country.